CA3015347A1 - Formulations of antibody molecules to influenza virus - Google Patents

Formulations of antibody molecules to influenza virus Download PDF

Info

Publication number
CA3015347A1
CA3015347A1 CA3015347A CA3015347A CA3015347A1 CA 3015347 A1 CA3015347 A1 CA 3015347A1 CA 3015347 A CA3015347 A CA 3015347A CA 3015347 A CA3015347 A CA 3015347A CA 3015347 A1 CA3015347 A1 CA 3015347A1
Authority
CA
Canada
Prior art keywords
formulation
seq
antibody molecule
sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015347A
Other languages
English (en)
French (fr)
Inventor
Susan Sloan
Bi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of CA3015347A1 publication Critical patent/CA3015347A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3015347A 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus Pending CA3015347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299162P 2016-02-24 2016-02-24
US62/299,162 2016-02-24
PCT/US2017/019053 WO2017147248A1 (en) 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus

Publications (1)

Publication Number Publication Date
CA3015347A1 true CA3015347A1 (en) 2017-08-31

Family

ID=58264606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015347A Pending CA3015347A1 (en) 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus

Country Status (7)

Country Link
US (3) US20170240617A1 (cg-RX-API-DMAC7.html)
EP (1) EP3419663A1 (cg-RX-API-DMAC7.html)
JP (2) JP7104629B2 (cg-RX-API-DMAC7.html)
CN (1) CN109195629A (cg-RX-API-DMAC7.html)
AU (2) AU2017222564A1 (cg-RX-API-DMAC7.html)
CA (1) CA3015347A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017147248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
EP3169407A4 (en) 2014-07-15 2018-04-25 Medimmune, LLC Neutralizing anti-influenza b antibodies and uses thereof
WO2016196470A1 (en) 2015-06-01 2016-12-08 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3402513A4 (en) * 2016-01-13 2019-10-23 Medlmmune, LLC METHOD FOR THE TREATMENT OF INFLUENZA A
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN111393512B (zh) * 2020-03-24 2021-03-02 北京中科微盾生物科技有限责任公司 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
CN116589569B (zh) * 2023-03-06 2024-06-07 中国农业科学院兰州兽医研究所 一种抗h7n9亚型流感病毒ha蛋白的纳米抗体及其噬菌体展示文库的构建方法和应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
FI83662C (fi) 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP2518607B2 (ja) 1985-08-29 1996-07-24 雪印乳業株式会社 インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
CA2190502A1 (en) 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2517074A1 (en) 2003-02-27 2004-09-10 Yeda Research And Development Co., Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005033143A1 (ja) * 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
DK2261376T3 (da) 2003-11-04 2013-10-07 Univ Tulane Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
EP2530147B1 (en) 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CA2591992A1 (en) 2004-12-22 2006-06-29 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CA2637837A1 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
KR20090027216A (ko) 2006-06-16 2009-03-16 다우 아그로사이언시즈 엘엘씨 조류 인플루엔자 헤마글루티닌의 신규한 ｄｎａ 서열, 벡터, 및 단백질
AU2007332987B2 (en) 2006-08-14 2013-01-10 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
JP4625485B2 (ja) 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
WO2008091657A1 (en) 2007-01-23 2008-07-31 Academia Sinica Flu vaccines and methods of use thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
CA2687147C (en) 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
US7879326B2 (en) 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
ES2609818T3 (es) 2007-06-15 2017-04-24 Xiamen University Anticuerpos monoclonales que se unen a hemaglutinina del virus de la gripe aviar del subtipo H5 y usos de los mismos
EP2207804B1 (en) 2007-09-13 2015-07-22 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
SG183032A1 (en) 2007-09-13 2012-08-30 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to hemagglutininand neuraminidase from influenza virus h5-subtypeor n1-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
AU2008331673B2 (en) 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
CN102015765B (zh) 2008-02-05 2015-01-28 淡马锡生命科学研究院有限公司 用于h5亚型流感病毒通用检测的结合蛋白和表位阻断elisa
WO2009111865A1 (en) 2008-03-12 2009-09-17 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009119722A1 (ja) 2008-03-28 2009-10-01 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
FI20080333A0 (fi) 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2574344A1 (en) 2008-07-11 2013-04-03 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
AU2009275227A1 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
US20100061995A1 (en) 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
GB0818356D0 (en) 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
WO2010040281A1 (zh) 2008-10-09 2010-04-15 厦门大学 H5亚型禽流感病毒血凝蛋白的人源化抗体及其用途
MX2011003855A (es) 2008-10-22 2011-12-16 Inst Research In Biomedicine Metodos para producir anticuerpos a partir de celulas plasmaticas.
US8540995B2 (en) 2008-12-24 2013-09-24 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
CN102264896B (zh) 2008-12-25 2014-02-26 国立大学法人大阪大学 抗人流感病毒人型抗体
WO2010127252A2 (en) 2009-04-30 2010-11-04 Vanderbilt University Monoclonal antibodies to influenza h1n1 virus and uses thereof
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2448596B1 (en) 2009-07-02 2016-01-06 Massachusetts Institute of Technology Compositions and methods for diagnosing and/or treating influenza infection
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
EP2486054A4 (en) 2009-10-09 2013-09-11 Univ Emory Recombinant antibodies against h1n1 influenza
WO2011068143A1 (ja) 2009-12-03 2011-06-09 独立行政法人科学技術振興機構 Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011094445A1 (en) 2010-01-27 2011-08-04 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
WO2011093217A1 (ja) 2010-01-29 2011-08-04 富士レビオ株式会社 抗Pandemic (H1N1) 2009抗体及びそれを用いた免疫測定方法
JPWO2011096302A1 (ja) 2010-02-02 2013-06-10 国立大学法人名古屋大学 薬剤耐性インフルエンザウイルス特異的抗体及びその用途
JP2011160681A (ja) 2010-02-05 2011-08-25 Japan Science & Technology Agency Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用
KR101297784B1 (ko) 2010-03-08 2013-08-20 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 인간 단일클론 항체
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
KR101849738B1 (ko) 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 수동 인플루엔자 면역에 유용한 항체
JP2013540701A (ja) 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
SG187769A1 (en) 2010-08-23 2013-03-28 Temasek Life Sciences Lab Ltd Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP2640405A4 (en) 2010-09-21 2015-04-15 Massachusetts Inst Technology HA-POLYPEPTIDES ADAPTED TO HUMANS, VACCINES THEREOF AND INFLUENZA TREATMENT THEREWITH
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2012054745A1 (en) 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
EP2646050B1 (en) 2010-12-02 2016-09-07 mAB-Factory GmbH Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections
CA2824389A1 (en) 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
EP3418300B1 (en) 2011-07-18 2020-10-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2739312B1 (en) 2011-08-03 2017-10-04 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
CN103030693B (zh) 2011-09-30 2015-03-11 中国科学院上海巴斯德研究所 高致病性禽流感的中和分子及其制备方法
EA026527B1 (ru) 2011-09-30 2017-04-28 Селлтрион Инк. Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека
US9321829B2 (en) 2011-10-18 2016-04-26 Emory University Antibodies directed against influenza
KR20130059721A (ko) 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
CN104245731B (zh) 2012-01-31 2017-04-05 株式会社医学生物学研究所 抗乙型流感病毒的广泛保护性人单克隆抗体及其使用方法
JP6328061B2 (ja) 2012-03-08 2018-05-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｂ型インフルエンザウイルスに結合して中和することができるヒト結合分子およびその使用
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
WO2014011846A2 (en) * 2012-07-12 2014-01-16 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Wavelength and power scalable waveguiding-based infrared laser system
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014124319A2 (en) 2013-02-07 2014-08-14 Massachusetts Institute Of Technology Human adaptation of h5 influenza
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
RU2682049C2 (ru) 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
MX365658B (es) 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2016246065B2 (en) 2015-04-08 2021-06-03 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR102084109B1 (ko) 2015-12-15 2020-03-03 시오노기세야쿠 가부시키가이샤 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20230257449A1 (en) 2019-12-11 2023-08-17 Visterra, Inc. Compositions and methods for treating and preventing influenza

Also Published As

Publication number Publication date
EP3419663A1 (en) 2019-01-02
CN109195629A (zh) 2019-01-11
JP2022110149A (ja) 2022-07-28
US20170240617A1 (en) 2017-08-24
AU2024202246A1 (en) 2024-06-27
WO2017147248A1 (en) 2017-08-31
AU2017222564A1 (en) 2018-09-06
US20200181243A1 (en) 2020-06-11
US12202885B2 (en) 2025-01-21
JP7104629B2 (ja) 2022-07-21
US20210054053A1 (en) 2021-02-25
JP2019512012A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US12202885B2 (en) Formulations of antibody molecules to influenza virus
US12024552B2 (en) Ha binding agents
US10513553B2 (en) Compositions and methods for treating and preventing influenza
US11230593B2 (en) Compositions and methods for treating and preventing influenza
US20230257449A1 (en) Compositions and methods for treating and preventing influenza
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220222

EEER Examination request

Effective date: 20220222

EEER Examination request

Effective date: 20220222

EEER Examination request

Effective date: 20220222

EEER Examination request

Effective date: 20220222

EEER Examination request

Effective date: 20220222